Back to Results

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and other acute cannabis-related conditions in the United States. Its lead candidate, selonabant, is a small-molecule antagonist of the CB1 receptor and is being evaluated in a phase II clinical trial as a potential antidote for cannabis toxicity. Incorporated in 2020, the company is headquartered in Lakeway, Texas. The listed security is common stock of Anebulo Pharmaceuticals Inc on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-ANEB
$0.37
13.1% Upside
Fair
$3
811.9% Upside
Bargain
Fair
—
—
—
0.0%
September 23, 2026
-1.7x
1.7x
—
13.439 M
4.417 M
0.0%
59.2%
-8.4
—
73.2%
Valuation • Fair Value

Anebulo Pharmaceuticals Inc (OTC-ANEB) Fair Value by Valuation Model

Compare the primary fair value estimate for Anebulo Pharmaceuticals Inc (OTC-ANEB) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.37

Estimated upside of 13.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.37

Comparable-company valuation reference.

Analyst Price Target

$3

Analysts imply upside of 811.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Anebulo Pharmaceuticals Inc (OTC-ANEB) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Anebulo Pharmaceuticals Inc (OTC-ANEB)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Anebulo Pharmaceuticals Inc (OTC-ANEB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Anebulo Pharmaceuticals Inc (OTC-ANEB)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-8.4

Lower score that deserves closer risk review.

FCF / Net Income

73.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Anebulo Pharmaceuticals Inc (OTC-ANEB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Anebulo Pharmaceuticals Inc (OTC-ANEB)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 23, 2026

Days to Earnings

64

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Anebulo Pharmaceuticals Inc (OTC-ANEB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Anebulo Pharmaceuticals Inc (OTC-ANEB) Stock Forecast & Technical Outlook

Review Anebulo Pharmaceuticals Inc (OTC-ANEB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Anebulo Pharmaceuticals Inc (OTC-ANEB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Anebulo Pharmaceuticals Inc (OTC-ANEB) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Anebulo Pharmaceuticals Inc (OTC-ANEB) Stock FAQ

Quick answers about Anebulo Pharmaceuticals Inc (OTC-ANEB) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.37
Estimated upside 13.1%
Valuation Rating
Undervalued
Estimated upside of 13.1%
Analyst Target
$3
Implied upside 811.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Anebulo Pharmaceuticals Inc (OTC-ANEB) is $0.37. This implies an estimated upside of 13.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.1% versus the current market price.

The available analyst price target for Anebulo Pharmaceuticals Inc (OTC-ANEB) is $3. The analyst target implies estimated upside of 811.9%.

The current financial health read for Anebulo Pharmaceuticals Inc (OTC-ANEB) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Anebulo Pharmaceuticals Inc (OTC-ANEB) is September 23, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Anebulo Pharmaceuticals Inc (OTC-ANEB) is -1.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Anebulo Pharmaceuticals Inc is 13.439 M.

The current enterprise value listed for Anebulo Pharmaceuticals Inc is 4.417 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Anebulo Pharmaceuticals Inc is OTC-ANEB, and the stock is listed on OTC Markets.

Anebulo Pharmaceuticals Inc (OTC-ANEB) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Anebulo Pharmaceuticals Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Anebulo Pharmaceuticals Inc is 59.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)